Skip to main content

Day: August 13, 2024

LiveOne (Nasdaq: LVO) Reports Q1 Fiscal 2025 Revenue of $33.1M

Adjusted EBITDA* (excluding CPS) of $3.3MAudio Division (Slacker Radio and PodcastOne (Nasdaq: PODC))Record Revenue of $31.9M (+24% YoY) Adjusted EBITDA* of $5.1MFiscal 2025 GuidanceConsolidated Revenue of $140M – $155M, Adj. EBITDA* of $16M – 20M Audio Division Revenue of $130M – $140M, Adj EBITDA* of $20M – $25MShares RepurchasedTotal shares 4.38M $6.3M remaining of $12M under repurchase programSenior Management to Host a Live Conference Call and Audio Webcast on Tuesday, August 13, 2024 at 10:00 A.M. ETLOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) — LiveOne (Nasdaq: LVO), an award-winning, creator-first, music, entertainment, and technology platform, announced today its operating results for the first fiscal quarter ended June 30, 2024 (“Q1 Fiscal 2025”). LiveOne’s CEO and Chairman, Robert...

Continue reading

PodcastOne (Nasdaq: PODC) Reports Q1 FY 2025 Record Revenue of $13.2M (+25% YoY)

Adjusted EBITDA* of $(0.3M) Signed $24M revenue B2B partnership with Fortune 250 company Expanded pipeline of podcasts ready to be adapted in TV and film projects Added 9 New Podcasts, Total Now at 187 Sold Another Successful Show to a Top 5 Streaming Platform FY 2025 Revenue Guidance of $51-56M Senior Management to Host a Live Conference Call and Audio Webcast at 11:30 A.M. ET on Tuesday, August 13, 2024LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) — PodcastOne (Nasdaq: PODC), a leading podcast platform and a subsidiary of LiveOne (Nasdaq: LVO), announced today its operating results for the first fiscal quarter ended June 30, 2024 (“Q1 FY 2025”). PodcastOne’s President and Co-Founder, Kit Gray, commented, “Once again, I am extremely proud of our team’s accomplishments. We’ve seen record-breaking revenue figures backed by...

Continue reading

Bitcoin Depot Reports Second Quarter 2024 Financial Results

Revenue of $163.1 Million With a Significant Expansion in Net Income to $4.4 Million Compared to Q1 2024 Exceeded Goal of Having Over 8,000 Active Bitcoin ATMs Five Months Ahead of Schedule ATLANTA, Aug. 13, 2024 (GLOBE NEWSWIRE) — Bitcoin Depot Inc. (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today reported financial results for the second quarter ended June 30, 2024. Bitcoin Depot will host a conference call and webcast at 10:00 a.m. ET today. An earnings presentation and link to the webcast will be made available at ir.bitcoindepot.com. “We continued to build on our momentum in the second quarter, achieving notable sequential growth in revenue, net income, and Adjusted EBITDA,” said Brandon Mintz, CEO and Founder of Bitcoin Depot. “Our success of having over 8,000 active...

Continue reading

Intuitive Machines Reports Second Quarter 2024 Financial Results; Raises Low-end of 2024 Revenue Outlook

Achieved $41.4 million of revenue in Q2, up 130% YoY; $114.5 million year to date, more than all of 2023Raised low-end of full-year 2024 revenue outlook to $210 – $240 million, resulting in 2.6x – 3x prior year salesQ2 ending cash balance and milestone payments on existing contracts expected to be sufficient to fund operations through the next 12 monthsCurrently zero debt on the balance sheet; paid down $5 million debt in Q2; remaining $3 million paid in JulyContinued mission two assembly, integration and testing; completed engine qualification; received contract modifications of $12.5 million for landing site selection; expected shipment of the completed lander to the launch site in Q4Signed $18 million in commercial rideshare delivery services since Q1, sold out mission two and continuing to sell rideshare capacity...

Continue reading

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the acquisition of economic interests in XACIATO™ (clindamycin phosphate) vaginal gel 2%, and two novel Phase 3 assets, from Daré Bioscience Completed the acquisition of Kinnate Pharmaceuticals, adding several potential royalty streams, as well as more than $9.5 million in non-dilutive capital EMERYVILLE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its second quarter 2024 financial results and highlighted recent activities.  “The second quarter was marked by pipeline progress, the realization of several cash milestones, the addition of three commercial or...

Continue reading

Middlefield Banc Corp. Announces 2024 Third-Quarter Cash Dividend Payment

MIDDLEFIELD, Ohio, Aug. 13, 2024 (GLOBE NEWSWIRE) — Middlefield Banc Corp. (NASDAQ: MBCN) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per common share. The third-quarter dividend is payable on September 13, 2024, to shareholders of record on August 30, 2024. About Middlefield Banc Corp. Middlefield Banc Corp., headquartered in Middlefield, Ohio, is the Bank holding Company of The Middlefield Banking Company, with total assets of $1.83 billion at June 30, 2024. The Bank operates 21 full-service banking centers and an LPL Financial® brokerage office serving Ada, Beachwood, Bellefontaine, Chardon, Cortland, Dublin, Garrettsville, Kenton, Mantua, Marysville, Middlefield, Newbury, Orwell, Plain City, Powell, Solon, Sunbury, Twinsburg, and Westerville. The Bank also operates a Loan Production...

Continue reading

Notice of Nexstim Plc’s Half-Year Report H1 2024

Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) will publish its half-yearly report for the six months ended 30 June 2024 on Friday 16 August 2024 at approximately 9:00 am Finnish time. The company will hold two live webinars for media, investors, and analysts on Friday 16 August 2024. CEO Mikko Karvinen and CFO Joonas Juokslahti will present the financial and operational results followed by a Q&A session. The first live webinar will be in Finnish, and it takes place at 10:30 am EEST. The second live webinar will be in English at 3 pm EEST. Webinar details: To attend the webinars, please access the webinar pages linked below. Through the same link, you can access webinar registration before the event, the...

Continue reading

The court terminated reorganization proceedings for MPG AgroProduction OÜ

On 28 November 2023, AS Tallinna Sadam (hereinafter referred to as “Tallinna Sadam”) submitted an application to initiate bankruptcy proceedings of MPG AgroProduction OÜ (hereinafter referred to as “MPG”). On 19 January 2024, the debtor submitted its reorganization application. On 12 August 2024, the reorganization proceedings of MPG were terminated by the Supreme Court’s order. In connection with the termination of MPG’s reorganization proceedings, the bankruptcy proceedings of MPG continue in Harju District Court. Bankruptcy proceedings were initiated on 28 November 2023 based on the application submitted by Tallinna Sadam, as MPG has not fulfilled its contractual obligations for a long time. The total amount of the claims is 3.5 million euros and it mainly consists of the outstanding debt of the...

Continue reading

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies Longer recall intervals for PRO assessments are less burdensome to clinical study participants and may improve data collection compliance SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder (FSAD), has been published by The Journal of Sexual Medicine. Publication Details: Johnson,...

Continue reading

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

NAVIGATE trial on track for interim top-line analysis in December 2024NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, “We continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first half of 2024. We believe that belapectin can potentially offer a new medical treatment option for the increasing number of patients affected with MASH associated liver cirrhosis and portal hypertension that represents a significant unmet medical need, and we are excited for the planned upcoming interim analysis in December 2024.” Khurram...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.